The effectiveness of Aqua Maris Ectoin in patients with allergic
rhinitis and sensitization to pollen allergens
AbstractThe aim of the work is to evaluate the effectiveness of Aqua Maris Ectoin® in patients with AR and sensitization to pollen allergens.
Material and methods. In May of 2018, an open, pilot study of the effectiveness of the nasal spray Aqua Maris Ectoin® was conducted in 30 patients with allergic rhinitis (AR).
Results. All patients (except one) showed a decrease in the intensity of all clinical symptoms of AR. After a week of use of nasal spray Aqua Maris Ectoin® range of eosinophils in the rhinocytogram has not changed. However, the average number of eosinophils tended (statistically unreliable) to decrease: from 29 ± 9 to 22 ± 10%. Among of the 30 patients, 16% (5 out of 30) had an increase in the number of eosinophils in the nasal secretion, 27% (8 out of 30) had no change in the picture, and 57% (17 out of 30) had a decrease in eosinophils.
Conclusion. The general trend towards positive clinical dynamics allows us to recommend the appointment of nasal spray Aqua Maris Ectoin® for improving the barrier function of the nasal mucosa.
Keywords:allergic rhinitis; aeroallergens; pollen; ectoin
Received 21.01.2019. Accepted 16.02.2019.
For citation: Mokronosova MA., Zheltikova T.M. The effectiveness of Aqua Maris Ectoin in patients with allergic rhinitis and sensitization to pollen allergens. Immunologiya. 2019; 40 (2): 38-42. doi: 10.24411/0206-4952-2019-12006. (in Russian)
Acknowledgments. The study had no sponsorship.
Conflict of interest. The authors declare no conflict of interest.
References
1. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63 (86): 8-160.
2. Bocking C., Renz H., Pfefferle PI., Pravalenz und soziookonomische Bedeutung von Allergien in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012; 55 (3): 303-7.
3. Angier E., Willington J., Scadding G., Holmes S., et al. Management of allergic and non-allergic rhinitis: a primary care summary of the BSACI guideline. Prim. Care Respir. J. 2010; 19 (3): 217-22.
4. DEGAM, Rhinosinusitis DEGAM-Leitlinie No. 10, vol. 053/012. Omikron, Dusseldorf, Germany, 2008.
5. Calderon M.A., Rodriguez del Rio P, Demoly P. Topical nasal corticosteroids versus oral antihistamines for allergic rhinitis. Cochrane Database Syst. Rev. 2010: CD008232.
6. Mokronosova M.A., Zheltikova T.M., Arefyeva A.S., Tarasova G.D. Therapeutic effect of Aqua Maris ECOIN in patients with allergic intermittent rhinitis. Rossiyskaya otorinolaringologiya. 2017; 87 (2): 142-8. (in Russian)
7. Bitop, Ectoin-The Natural Stress-Protection Molecule, Scientific Information. Witten, Germany, 2010.
8. Smiatek J., Harishchandra R.K., Rubner O., Galla H.-J., et al. Properties of compatible solutes in aqueous solution. Biophys. Chem. 2012; 160 (1): 62-8.
9. Harishchandra R.K., Sachan A.K., Kerth A., Lentzen G., et al. Compatible solutes: ectoine and hydroxyectoine improve functional nanostructures in artificial lung surfactants. Biochim. Biophys. Acta. 2011; 1808 (12): 2830^0.
10. Dirschka T. Ectoin-Anwendung und Perspektiven fur die Dermatologie. Aktuelle Dermatol. 2008; 34 (4): 115-8.
11. Lentzen G., Schwarz T. Extremolytes: natural compoundsfrom extremophiles for versatile applications. Appl. Microbiol. Biotechnol. 2006; 72 (4): 623-34.
12. Eichel A., Bilstein A., Werkhauser N., Mosges R. Metaanalysis of the efficacy of ectoine nasal spray in patients with allergic rhinoconjunctivitis. J. Allergy (Cairo). 2014; 2014: 292545. doi: 10.1155/2014/292545.